WSJ: Secret hospital contracts prevent healthcare savings

Healthcare costs continue to balloon in the United States, and secret contracts between hospital systems and insurers may be playing a big role in keeping those costs up.

Large hospital systems are leveraging their contracts with insurers to “protect their turf and block efforts to curb healthcare costs,” according to a report from The Wall Street Journal. Through strict language in contracts between payers and providers, hospitals are actively excluding the use of less-expensive rivals and adding extra fees to boot.

These opaque methods may be a driver of higher spending, according to the WSJ. Restrictive contracts are causing major obstacles for big companies looking to lower healthcare costs for their own employees, including Walmart and Home Depot, the report found. Major hospital systems, from Johns Hopkins to NewYork-Presbyterian, participate in such restrictive contracts that give them a leg up.

“If you’re the single hospital system in an area, you essentially can set your price, because you’re a monopoly,” Patrick Conway, the chief executive of Blue Cross and Blue Shield of North Carolina, told the WSJ. “We literally have to have them in network.”

Hospital care accounts for more than $1 trillion in healthcare spending annually, and prices grew about three times the rate of inflation from 1960 to 2016. The outsized spending is particularly concerning when contracts are so private.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.